Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients

Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients

BACKGROUND: Tacrolimus is a first-line immunosuppressive therapy to prevent rejection and graft failure in kidney transplant recipients. Once-daily extended-release tacrolimus tablets (LCPT) have been shown to be efficacious, particularly for Hispanic and Black patient subpopulations who are rapid m...

Full description

Bibliographic Details
Main Authors: Grizzle, A.J (Author), Hurwitz, J.T (Author), Malone, D.C (Author), Tyler, C.S (Author), Zapata, L.V (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
acute graft rejection
African American
African Americans
aged
Article
Black person
clinical trial
cost benefit analysis
cost effectiveness analysis
Cost-Benefit Analysis
cotrimoxazole
decision making
decision support system
Decision Support Techniques
decision tree
dialysis
dosage schedule comparison
drug administration
Drug Administration Schedule
drug cost
drug release
economics
female
graft failure
Hispanic
Hispanic Americans
human
Humans
immunosuppressive agent
Immunosuppressive Agents
immunosuppressive treatment
kidney graft
kidney transplantation
Kidney Transplantation
major clinical study
male
methylprednisolone
nystatin
opportunistic infection
peak-trough fluctuation
phase 3 clinical trial (topic)
prednisone
Prospective Studies
prospective study
sensitivity analysis
tablet
tacrolimus
Tacrolimus
United States
valganciclovir
Willingness To Pay
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items